News
23h
GlobalData on MSNNovartis culls ianalumab in HS after Phase IIb trial failureNovartis is stopping the development of ianalumab in hidradenitis suppurativa (HS) after a Phase IIb proof-of-concept trial ...
18h
Just Auto on MSNChina drives global vehicle market up in June – GlobalData"China drives global vehicle market up in June – GlobalData" was originally created and published by Just Auto, a GlobalData ...
Localising and automating supply chains will allow companies to mitigate the impact of tariffs and minimise resulting costs.
Following today’s release of DFS’ figures for the 52 weeks ending 29 June 2025; Matt Walton, senior retail analyst at ...
Pharmaceutical companies and manufacturers, including MilliporeSigma (Burlington, US), Simtra BioPharma Solutions (Parsippany, US), Carbogen AMCIS (Bubendorf, Switzerland), and BioNTech (Mainz, ...
1d
Al Jazeera on MSNTesla finally parks in India. But can it survive?Elon Musk’s EV giant has launched its Model Y in Mumbai, but its $70,000 price tag may be its biggest speed bump.
The wellness trend is driving demand for functional, protein-rich foods like yogurt. Here’s what’s fueling growth in the ...
Experian (EXPN), Barratt Redrow (BTRW), B&M European Value (BME), GlobalData (DATA), Robert Walters (RWA), Mobico (MCG), ...
17h
Clinical Trials Arena on MSNSarepta share price drops again after third gene therapy deathSarepta Therapeutics’ share price has fallen again following the death of a third patient dosed with its gene therapy ...
The success of the post-growth model is reliant on transparency, clear and honest communication with customers and supplier collaboration.
3d
GlobalData on MSNCaranx Medical’s AI TAVI-TAVR software gains FDA approvalThe US Food and Drug Administration (FDA) has cleared Caranx Medical’s TAVIPILOT Soft, an artificial intelligence (AI)-based guide software for use during Transcatheter Aortic Valve Implantation (TAVI ...
3d
Pharmaceutical Technology on MSNSino Biopharma spends $951m to acquire China-based LaNova MedicinesBoth AstraZeneca and MSD have tied lucrative licensing deals for two of LaNova’s oncology assets in recent years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results